Six GLP-1-1-subjected astrogens are included in the health insurance catalog

Glucagon-like peptide 1 (GLP-1) is a kind of "intestinal-promoting tryptoprene" naturally secreted by the mucosa of the human gastrointestinal tract, which binds to the ligands on islet cells and stimulates insulin secretion, which in turn produces a lower blood sugar effect.
GLP-1 inhibitor-type sugar-lowering drugs have the advantage that the rate of hypoglycemia events is significantly lower than insulin, and can reduce food intake and delay stomach emptying, is conducive to weight control, can protect islet β cell function.
GLP-1-1-subjected astrogenic antisaccharides include short-acting and long-lasting drugs.
The short-term effects currently approved for domestic market are Essena peptide (2 times daily), liraglutide (1 time per day), benaglutide (3 times a day), lisnaptide (1 time per day);
the short-acting GLP-1 liraglutide was included in the 2017 version of the health insurance catalog for $410 per branch and successfully renewed the 2019 version of the health insurance catalog, lisnapeptide and Essena peptide were also included in the 2019 version of the health insurance catalog.
the latest news, Benaglutide, doraglutide and polyethyl glycol locena peptide negotiated successfully and entered the 2020 edition of the health care catalog.
, a total of six GLP-1s have been included in the health insurance list.
。